相关实验视频

Updated: May 22, 2025

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

CD103+CD56+ILC与瘤微环境中的改变的CD8+T细胞配置相关

Douglas C Chung^1,2, Noor Shakfa³, Jehan Vakharia²

¹Department of Immunology, University of Toronto, Toronto, Canada.

Cancer immunology research

|March 14, 2025

概括

研究人员发现了一种新型的表达CD103+CD56+的先天性淋巴细胞 (ILC),可以在瘤微环境 (TME) 中抑制抗瘤免疫力. 这一发现可能会导致改进的癌症免疫疗法.

科学领域:

免疫学免疫学免疫学
癌症生物学癌症生物学
细胞生物学细胞生物学

背景情况:

免疫疗法在癌症治疗中表现有前途,但反应率有变化.
了解瘤微环境 (TME) 对于提高抗瘤免疫力至关重要.
天生的淋巴细胞 (ILC) 和自然杀手细胞 (NK) 在免疫中起着调节作用.

研究的目的:

在TME中识别影响抗瘤反应的新型免疫细胞群.
描述表达CD103的独特ILC子集及其功能含义.

主要方法:

利用流式细胞计量来识别CD103+CD56+细胞.
采用单细胞多核和空间分析来分析ILC和相关免疫细胞.
在培养中评估了瘤透淋巴细胞的增殖能力.

主要成果:

确定了CD103+CD56+ILCs作为一个独特的群体,具有独特的分子和转录基因特征.
这些CD103+CD56+ILC与降低的CD8+T细胞活性 (granzyme B表达) 有关.
CD103+CD56+ ILCs与瘤透性淋巴细胞增殖不良的相关性在体外.

结论:

发现了一种新的CD103+CD56+ ILC子集,在TME中具有潜在的抑制功能.
这种ILC群体与表现出抗瘤活性减弱的CD8+T细胞有关.
对这些抑制性ILC的进一步研究可能会揭示提高癌症免疫疗法疗效的策略.

更多相关视频

Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model

Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model

Published on: April 13, 2015

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Published on: June 13, 2019

相关概念视频

T Cell Activation and Clonal Selection

T Cell Activation and Clonal Selection

T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

The Tumor Microenvironment

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...